Navigation Links
Today's Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics

LONDON, March 6, 2013 /PRNewswire/ --

On Tuesday, the markets retained their bullish mode as indices created yet another life-time high. The markets showed across the board improvement, and the Healthcare sector saw Johnson & Johnson creating a new all time high. The Dow Jones ended its latest session at 14,253.77, up 0.89 percent while NASDAQ was up 1.32 percent to close at 3,224.13. Similarly, S&P closed on a positive note at 1,539.79, up 0.96 percent. Our research team took a look at the Healthcare sector, focusing on the biotech Industry which includes major companies like PDL BioPharma Inc. (NASDAQ: PDLI), Dendreon Corporation (NASDAQ: DNDN), Medivation Inc. (NASDAQ: MDVN), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Cell Therapeutics Inc. (NASDAQ: CTIC). StockCall professionals have completed their technical analysis on PDLI, DNDN, MDVN, ACAD and CTIC and these free reports are accessible by registering at  

On top of ending its previous trading session flat, PDL BioPharma Inc. is still down 0.85 percent for the year. However, the stock has grown 6.16 percent in the past 52 weeks. PDLI closed flat at $6.98 on volume of 2.56 million shares on Tuesday. Its average trading volume stands at 2.01 million shares. PDL BioPharma's shares currently face resistance at around $7.04. The stock has support at around $6.89. It is currently trading above its 20-day, but below 50-day moving averages, which is a neutral signal. Sign up for the free technical research on PDLI at

Dendreon Corporation traded in the range of $5.61 and $5.85 during Tuesday's trading session. It opened at $5.75 and closed at $5.70, down 0.35 percent. The stock is currently in a neutral mode and has its first resistance level at $5.80. Upon breaching this level, the company may go as high as $6.03. It traded 3.47 million shares and is above its 20-day moving average price. Its first support level is at $5.42. So far in 2013, the stock is up 7.75 percent. Be sure to read our latest technical research on DNDN by registering at

Despite the upward movement shown by broad market indices, Medivation Inc.'s stock finished 2.47 percent lower at $45.86, with volume up from daily average of 1.50 million to 3.64 million. The biotech company's stock is down so far in 2013 with a year-to-date decline at 10.36 percent. However, the stock currently shows a bearish trend which is further confirmed by the stock's MACD chart. Medivation has its first support level at $43.26. In the coming trading sessions, the stock is likely to go as high as $49.09. Sign up and read the complimentary report on MDVN at

ACADIA Pharmaceuticals Inc.'s stock rose mildly in its latest trading session. The stock closed 0.63 percent higher at $6.37 with 1.48 million share volume. Despite the mild upward movement, the stock is still up more than 36 percent for the year. In the past 52 weeks, the company's stock is up 300 percent. The stock currently has support at $6.28 level. The stock's MACD chart shows a neutral trend. ACADIA may face its first resistance level at $6.75. Upon breaching this level, the stock may go as high as $7.03. The free report on ACAD can be downloaded by signing up now at

Shares of Cell Therapeutics Inc. ended flat in Tuesday's trading session. The stock closed at $1.26 on below average volume of 966,000 shares. The company's shares have lost more than 3 percent this year, underperforming the broad market. It has support at $1.15. Despite the flat ending, Cell Therapeutics' shares are still trading below their 50-day and 200-day moving averages. Free report on CTIC can be accessed by registering at

About is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at  

Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Army Researcher Develops Potential Vaccine Carrier That May Give Stockpiling Efforts A Shot In The Arm
2. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
3. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
6. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
7. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
8. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
9. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
10. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
11. Okuma America Chooses The Daniel Group To Provide Customer Service Research
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015  Kevin Smith ... Sensium Healthcare, a global pioneer in wireless monitoring ... Boston, MA , Mr. Smith will ... Sensium,s global commercial strategy.  He will also directly ... to build clinical evidence for SensiumVitals, the first ...
(Date:11/30/2015)... , Nov. 30, 2015  The fee-for-service ... in U.S. medical imaging is on its ... accountable care payer-provider contracts are set to ... their wake, alter provider-vendor relationships. The shift ... push forward new purchasing frameworks in the ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top ... from Tufts School of Dental Medicine in 1935. His father graduated from NYU ... being in dentistry as well as their commitment and passion to the Practice of ...
(Date:11/30/2015)... York, NY (PRWEB) , ... November 30, 2015 , ... ... York Times,” will be released on December 1, 2015, to coincide with World AIDS ... about the groundbreaking journalist who covered the AIDS epidemic as he was dying of ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for ... honor of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a ... about World AIDS Day and the importance of getting tested for HIV. , ASCP ...
(Date:11/30/2015)... ... 30, 2015 , ... California-based i2i Systems, a pioneer defining ... Michigan-based Family Health Center (FHC) has selected i2iTracks as their population health management ... the largest Affordable Care Act grant for Federally Qualified Health Centers in the ...
Breaking Medicine News(10 mins):